Vice President of Translational Science
GentiBio
Karen is the Vice President of Translational Science and executive Program Leader for GNTI-122 at GentiBio. Karen led the clinical pharmacology and translational sciences team for cellular and gene therapies at Novartis Pharmaceuticals in both both early and stage late development. Karen was instrumental in leading the clinical pharmacology strategy for the first cellular therapy (CAR-T) approved in the United States, Europe, and Rest of World, including an Oncology Drug Advisory Committee. She has authored and co-authored numerous seminal papers in the field of cellular and gene therapy. In addition, Karen has led the early development of multiple ADCs and monoclonal antibodies and supported the clinical pharmacology strategies for Kisqali, Afinitor and other established products. Karen received her Doctor of Pharmacy and Master of Science in Pharmaceutical Sciences with a focus on Clinical Pharmacology, from the University of Rhode Island and completed post-doctoral fellowships at the Roswell Park Cancer Institute in Buffalo, the State University of New York Buffalo, and Novartis Pharmaceutical.
Disclosure information not submitted.
Tuesday, April 25, 2023
1:00 PM – 2:00 PM ET